Treatment with romosozumab is linked to improved BMD and a reduced risk for vertebral fractures among postmenopausal women with osteoporosis.

The European Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab.